Tryp Therapeutics Inc.
TRYPF · OTC
2/29/2024 | 11/30/2023 | 8/31/2023 | 5/31/2023 | |
|---|---|---|---|---|
| Market Cap | $2 | $5 | $7 | $8 |
| - Cash | $0 | $2 | $0 | $1 |
| + Debt | $0 | $5 | $2 | $1 |
| Enterprise Value | $2 | $8 | $8 | $8 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$0 | -$1 | -$1 | -$1 |
| % Margin | – | – | – | – |
| Net Income | -$0 | -$1 | -$2 | -$1 |
| % Margin | – | – | – | – |
| EPS Diluted | -0 | -0.012 | -0.018 | -0.007 |
| % Growth | 99.7% | 31.4% | -157.4% | – |
| Operating Cash Flow | -$0 | -$1 | -$1 | -$1 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$1 | -$1 | -$1 |